Literature DB >> 7882332

Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization.

M Tarkkanen1, R Karhu, A Kallioniemi, I Elomaa, A H Kivioja, J Nevalainen, T Böhling, E Karaharju, E Hyytinen, S Knuutila.   

Abstract

Our aim was to identify chromosomal regions that are likely to harbor previously unknown genes with an important role in the genesis of osteosarcoma. Comparative genomic hybridization was used to screen for losses and gains of DNA sequences along all chromosome arms in 11 tumors. Extensive genetic aberrations, with an average of 11 changes/tumor (range, 1-20), were found in 10 of the 11 specimens. High level amplifications of small chromosomal regions were detected in eight tumors. These involved the 12q12-q13 region (known to contain the SAS-MDM2 locus) and several previously unreported amplification sites such as 17p11-p12, 3q26, and Xq12. When all DNA sequence gains were evaluated, the gains at 8q and Xp were most common (45%). The most common losses of DNA sequences were seen at 2q, 6q, 8p, and 10p (36%). In conclusion, despite the very complex pattern of genetic changes in osteosarcomas, certain chromosomal regions appear to be affected more often than others. Most of these regions have not previously been reported to be implicated in osteosarcomas and may thus highlight locations of novel genes with an important role in the development and progression of these tumors.

Entities:  

Mesh:

Year:  1995        PMID: 7882332

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.

Authors:  M L Larramendy; M Tarkkanen; C Blomqvist; M Virolainen; T Wiklund; S Asko-Seljavaara; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas.

Authors:  M L Larramendy; M Tarkkanen; J Valle; A H Kivioja; H Ervasti; E Karaharju; T Salmivalli; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 3.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies.

Authors:  S Knuutila; A M Björkqvist; K Autio; M Tarkkanen; M Wolf; O Monni; J Szymanska; M L Larramendy; J Tapper; H Pere; W El-Rifai; S Hemmer; V M Wasenius; V Vidgren; Y Zhu
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

4.  The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma.

Authors:  Shamini Selvarajah; Maisa Yoshimoto; Paul C Park; Georges Maire; Jana Paderova; Jane Bayani; Gloria Lim; Khaldoun Al-Romaih; Jeremy A Squire; Maria Zielenska
Journal:  Chromosoma       Date:  2006-08-09       Impact factor: 4.316

5.  Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.

Authors:  Jennifer A Byrne; Yuyan Chen; Nancy Martin La Rotta; Gregory B Peters
Journal:  Genes Cancer       Date:  2012-02

6.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

7.  Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma.

Authors:  Menglin Cong; Jianmin Li; Rui Jing; Zhenzhong Li
Journal:  Tumour Biol       Date:  2016-01-19

8.  The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.

Authors:  Michael Overholtzer; Pulivarthi H Rao; Reyna Favis; Xin-Yan Lu; Michael B Elowitz; Francis Barany; Marc Ladanyi; Richard Gorlick; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

9.  Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.

Authors:  Xin-Yan Lu; Yaojuan Lu; Yi-Jue Zhao; Kim Jaeweon; Jason Kang; Li Xiao-Nan; Gouqing Ge; Rene Meyer; Laszlo Perlaky; John Hicks; Murali Chintagumpala; Wei-Wen Cai; Marc Ladanyi; Richard Gorlick; Ching C Lau; Debananda Pati; Michael Sheldon; Pulivarthi H Rao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

10.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.

Authors:  Ou Ma; Wei-Wen Cai; Lars Zender; Tajhal Dayaram; Jianhe Shen; Alan J Herron; Scott W Lowe; Tsz-Kwong Man; Ching C Lau; Lawrence A Donehower
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.